D. E. Shaw & Co. Inc. Takes $301,000 Position in Tocagen Inc (TOCA)

D. E. Shaw & Co. Inc. acquired a new position in shares of Tocagen Inc (NASDAQ:TOCA) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 36,764 shares of the company’s stock, valued at approximately $301,000. D. E. Shaw & Co. Inc. owned approximately 0.18% of Tocagen at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of TOCA. Foresite Capital Management III LLC grew its holdings in shares of Tocagen by 347.8% during the fourth quarter. Foresite Capital Management III LLC now owns 665,219 shares of the company’s stock worth $5,461,000 after purchasing an additional 516,667 shares in the last quarter. Citigroup Inc. grew its holdings in shares of Tocagen by 1,917.8% during the fourth quarter. Citigroup Inc. now owns 457,246 shares of the company’s stock worth $3,754,000 after purchasing an additional 434,585 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Tocagen by 25.2% during the third quarter. BlackRock Inc. now owns 1,413,285 shares of the company’s stock worth $22,033,000 after purchasing an additional 284,518 shares in the last quarter. Federated Investors Inc. PA grew its holdings in shares of Tocagen by 608,444.7% during the third quarter. Federated Investors Inc. PA now owns 231,247 shares of the company’s stock worth $3,605,000 after purchasing an additional 231,209 shares in the last quarter. Finally, Hound Partners LLC purchased a new position in shares of Tocagen during the fourth quarter worth about $871,000. 36.88% of the stock is owned by institutional investors.

Several research analysts have recently commented on TOCA shares. B. Riley started coverage on Tocagen in a report on Monday, December 31st. They set a “buy” rating and a $22.00 price objective for the company. Zacks Investment Research raised Tocagen from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Tuesday, January 15th. Robert W. Baird started coverage on Tocagen in a report on Friday, January 18th. They set an “outperform” rating and a $20.00 price objective for the company. Finally, Leerink Swann started coverage on Tocagen in a report on Monday. They set a “market perform” rating and a $10.26 price objective for the company. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $18.58.

Shares of TOCA opened at $9.94 on Tuesday. The company has a market capitalization of $236.19 million, a price-to-earnings ratio of -4.07 and a beta of 3.50. The company has a quick ratio of 5.91, a current ratio of 5.91 and a debt-to-equity ratio of 0.45. Tocagen Inc has a 1 year low of $6.47 and a 1 year high of $15.80.

Tocagen (NASDAQ:TOCA) last issued its earnings results on Wednesday, February 27th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.35). The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. Tocagen had a negative return on equity of 92.56% and a negative net margin of 271.43%. Sell-side analysts anticipate that Tocagen Inc will post -2.94 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.themarketsdaily.com/2019/04/16/d-e-shaw-co-inc-takes-301000-position-in-tocagen-inc-toca.html.

Tocagen Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Read More: How much money do you need to begin day trading?

Want to see what other hedge funds are holding TOCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tocagen Inc (NASDAQ:TOCA).

Institutional Ownership by Quarter for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.